Status:
WITHDRAWN
Efficacy and Safety of Tocilizumab for TAO
Lead Sponsor:
Sun Yat-sen University
Conditions:
Tocilizumab
Thyroid Associated Ophthalmopathy
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.
Detailed Description
Thyroid Associated Ophthalmopathy(TAO) is one of autoimmune orbital diseases characterized by enlargement of the extraocular muscles and increase in fatty or/and orbit connective tissue volume affecti...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age 18-70 years old
- Clinical diagnosis of Thyroid-associated ophthalmopathy
- Euthyroid status at least 1 months before baseline.
- No previous specific therapy for TAO, except for local measures
- Written informed consent is obtained
- Exclusion criteria:
- Uncontrolled diabetes or hypertension
- Renal or hepatic insufficiency.
- Infectious diseases (HIV, HBV,TB and so on)
- History of mental/psychiatric disorder
- Other ocular diseases or fundus diseases.
- Any previous systemic medications or surgery for the treatment of TAO
- Pregnant or lactating females.
- Intolerability of tocilizumab
Exclusion
Key Trial Info
Start Date :
September 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06087731
Start Date
September 23 2023
End Date
September 23 2023
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China